Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > MOR MorphoSys > Key Indicators
MOR MorphoSys
4.020
+0.160+4.15%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-- -- -- -- -- -- 60.87% -351.9068
Receivable Turnover(T)
-- -- -- 1.6196 1.92% 1.9828 -66.12% 2.2555
Inventory Turnover(T)
-- -- -- 1.7989 28.55% 2.0437 17.11% 2.0962
Fixed Assets Turnover(T)
-- -- -- 3.8955 46.00% 3.5282 -69.72% 3.5803
Total Asset Rate(T)
-- -- -- 0.0778 2.20% 0.0847 -71.97% 0.0852
ROIC
-- -- -- -- -419.91% -74.819% -514.04% -60.631%
ROE
-- -- -- -- -645.50% -165.098% -716.45% -118.786%
ROA
-- -- -- -33.940% -213.12% -28.998% -368.76% -24.406%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- -- -- -202.95% -30.830%
ROA 5 Year Average
-- -- -- -- -- -- -19.87% -12.578%
Average 5 Years ROIC
-- -- -- -- -- -- -82.31% -19.908%
Profitability Ratios TTM
Gross Margin
3.30% 82.929% -2.26% 78.398% -12.38% 79.850% -15.56% 82.075%
Operating Margin
37.78% -98.842% 7.57% -153.629% -4.93% -181.714% -2,921.57% -154.569%
Net Margin
-274.49% -345.258% -509.87% -436.394% -206.38% -342.462% -1,058.85% -286.429%
EBITDA Margin
-188.29% -2.0485% -885.09% -3.2979% -255.76% -3.2107% -839.83% -2.868%
R & D Expense Ratio
-1.75% 116.550% 25.20% 142.160% 20.02% 147.760% 190.52% 125.390%
Sales Expense Ratio
-45.40% 40.860% -33.37% 56.800% -33.40% 66.290% 105.81% 67.670%
Administration Expense Rate
-86.69% 6.080% -79.66% 9.690% -48.91% 21.290% 15.93% 18.190%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-- -- -- -- 316.97% 227.768% 159.70% 131.548%
Total Assets to Common Equity
-- -- -- -- 509.10% 1733.724% 290.84% 1043.898%
Debt to Asset Ratio
-- -- -- -- 318.51% 231.514% 159.78% 133.043%
Current Ratio
-- -- -51.39% 2.9845 -31.78% 4.241 -33.86% 3.9818
Quick Ratio
-- -- -53.91% 2.7117 -35.43% 3.915 -35.56% 3.7937
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- -- -52.89% 32.943%
Revenue CAGR(5Y)
-- -- -- -- -- -- 15.85% 29.277%
Currency Unit
EUREUREUREUR

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
MorphoSys AG operates as a commercial-stage biopharmaceutical company. It uses groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. The firm also engages in the development and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.
CEO: Mr. Jean-Paul Kress
Market: NASDAQ
Listing Date: 04/19/2018
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist